Similar articles for PMID: 29593890

Year	Number of Results
2012	1
2013	1
2015	1
2016	9
2017	11
2018	33
2019	40
2020	18
2021	23
2022	9
2023	5
2024	0

1

Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer.

Yeh J, Marrone KA, Forde PM. Yeh J, et al. J Thorac Dis. 2018 Feb;10(Suppl 3):S451-S459. doi: 10.21037/jtd.2018.01.109. J Thorac Dis. 2018. PMID: 29593890 Free PMC article. Review.

2

Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.

Melosky B, Juergens R, McLeod D, Leighl N, Brade A, Card PB, Chu Q. Melosky B, et al. Lung Cancer. 2019 Aug;134:259-267. doi: 10.1016/j.lungcan.2019.05.027. Epub 2019 May 29. Lung Cancer. 2019. PMID: 31319991 Review.

3

Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).

Ahern E, Cubitt A, Ballard E, Teng MWL, Dougall WC, Smyth MJ, Godbolt D, Naidoo R, Goldrick A, Hughes BGM. Ahern E, et al. Trials. 2019 Dec 19;20(1):753. doi: 10.1186/s13063-019-3951-x. Trials. 2019. PMID: 31856909 Free PMC article.

4

Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non-Small Cell Lung Cancer: Emerging Mechanisms and Perspectives.

Inoue H, Okamoto I. Inoue H, et al. Lung Cancer (Auckl). 2019 Dec 31;10:161-170. doi: 10.2147/LCTT.S184380. eCollection 2019. Lung Cancer (Auckl). 2019. PMID: 32099495 Free PMC article. Review.

5

Durvalumab for the treatment of non-small cell lung cancer.

Murakami S. Murakami S. Expert Rev Anticancer Ther. 2019 Dec;19(12):1009-1016. doi: 10.1080/14737140.2019.1699407. Epub 2019 Dec 3. Expert Rev Anticancer Ther. 2019. PMID: 31782989 Review.

6

Tumor PD-L1 expression is associated with outcomes in stage III non-small cell lung cancer (NSCLC) patients treated with consolidation durvalumab.

Jazieh K, Gad M, Saad A, Wei W, Pennell NA. Jazieh K, et al. Transl Lung Cancer Res. 2021 Jul;10(7):3071-3078. doi: 10.21037/tlcr-21-249. Transl Lung Cancer Res. 2021. PMID: 34430348 Free PMC article.

7

PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.

Xia L, Liu Y, Wang Y. Xia L, et al. Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05. Oncologist. 2019. PMID: 30819829 Free PMC article. Review.

8

Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).

Yoneda K, Imanishi N, Ichiki Y, Tanaka F. Yoneda K, et al. J UOEH. 2018;40(2):173-189. doi: 10.7888/juoeh.40.173. J UOEH. 2018. PMID: 29925736 Free article. Review.

9

Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study.

Wang CC, Chiu LC, Ju JS, Lin YC, Fang YF, Yang CT, Hsu PC. Wang CC, et al. Vaccines (Basel). 2021 Oct 1;9(10):1122. doi: 10.3390/vaccines9101122. Vaccines (Basel). 2021. PMID: 34696229 Free PMC article.

10

[IoNESCO trial: Immune neoajuvant therapy in early stage non-small cell lung cancer].

Mignard X, Antoine M, Moro-Sibilot D, Dayen C, Mennecier B, Gervais R, Amour E, Milleron B, Morin F, Zalcman G, Wislez M. Mignard X, et al. Rev Mal Respir. 2018 Nov;35(9):983-988. doi: 10.1016/j.rmr.2018.08.006. Epub 2018 Sep 20. Rev Mal Respir. 2018. PMID: 30243521 Free article. Clinical Trial. French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

145 results

Results by year